109 related articles for article (PubMed ID: 7171892)
21. [Immunologic evaluation of measles vaccine in preschool and school children].
Soto C; Cordero J; Vergara MI
Rev Chil Pediatr; 1981; 52(6):491-5. PubMed ID: 7347862
[No Abstract] [Full Text] [Related]
22. Potency status and efficacy of measles vaccine administered in Nigeria: a case study of three EPI centres in Lagos, Nigeria.
Omilabu SA; Oyefolu AO; Ojo OO; Audu RA
Afr J Med Med Sci; 1999; 28(3-4):209-12. PubMed ID: 11205835
[TBL] [Abstract][Full Text] [Related]
23. [Measles vaccination: study of humoral immunity in children vaccinated in the Tunis region].
Arrouji A; Mirchamsy H; Marnissi A
Arch Inst Pasteur Tunis; 1982 Mar; 59(1):173-80. PubMed ID: 7181563
[No Abstract] [Full Text] [Related]
24. [Serological study of postvaccinal measles immunity in the absence of a booster effect and in measles foci].
Chudnaia LM; Fastovskaia BN; Shekhter AB; Orekhova GI; Dzhulaĭ AS
Tr Inst Im Pastera; 1979; 53():71-5. PubMed ID: 262711
[No Abstract] [Full Text] [Related]
25. Comparative efficacy of three measles vaccines in Indian children.
Banerjee K; Shaikh N; Phadke M; Bedekar SS; Rauta SK; Mehta JM
Indian J Public Health; 1998; 42(4):113-9. PubMed ID: 10389523
[TBL] [Abstract][Full Text] [Related]
26. Optimal age for vaccinating Nigerian children against measles. I. Neonatal antibody profile and subsequent susceptibility to measles.
Harry TO; Ogunmekan DA
Trop Geogr Med; 1981 Dec; 33(4):375-8. PubMed ID: 7342384
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the immune response to a 2-dose measles vaccination schedule administered at 6 and 9 months of age to HIV-infected and HIV-uninfected children in Malawi.
Helfand RF; Witte D; Fowlkes A; Garcia P; Yang C; Fudzulani R; Walls L; Bae S; Strebel P; Broadhead R; Bellini WJ; Cutts F
J Infect Dis; 2008 Nov; 198(10):1457-65. PubMed ID: 18828743
[TBL] [Abstract][Full Text] [Related]
28. Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment.
LeBaron CW; Beeler J; Sullivan BJ; Forghani B; Bi D; Beck C; Audet S; Gargiullo P
Arch Pediatr Adolesc Med; 2007 Mar; 161(3):294-301. PubMed ID: 17339511
[TBL] [Abstract][Full Text] [Related]
29. Gender differences in the reactogenicity of measles-mumps-rubella vaccine.
Shohat T; Green MS; Nakar O; Ballin A; Duvdevani P; Cohen A; Shohat M
Isr Med Assoc J; 2000 Mar; 2(3):192-5. PubMed ID: 10774264
[TBL] [Abstract][Full Text] [Related]
30. Immune response to measles vaccine in 6 month old infants in Papua New Guinea.
Kurubi J; Vince J; Ripa P; Tefuarani N; Riddell M; Duke T
Trop Med Int Health; 2009 Feb; 14(2):167-73. PubMed ID: 19171008
[TBL] [Abstract][Full Text] [Related]
31. Antibody response after measles immunization.
Ariyasriwatana C; Kalayanarooj S; Pattamadilok S
J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S701-6. PubMed ID: 14700170
[TBL] [Abstract][Full Text] [Related]
32. Population immunity to measles in the United States, 1999.
Hutchins SS; Bellini WJ; Coronado V; Jiles R; Wooten K; Deladisma A
J Infect Dis; 2004 May; 189 Suppl 1():S91-7. PubMed ID: 15106096
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of vaccination at 6 to 11 months of age during an outbreak of measles.
de Serres G; Boulianne N; Ratnam S; Corriveau A
Pediatrics; 1996 Feb; 97(2):232-5. PubMed ID: 8584383
[TBL] [Abstract][Full Text] [Related]
34. Predicting and comparing long-term measles antibody profiles of different immunization policies.
Lee MS; Nokes DJ
Bull World Health Organ; 2001; 79(7):615-24. PubMed ID: 11477964
[TBL] [Abstract][Full Text] [Related]
35. Measles virus haemagglutination-inhibition antibodies among pregnant and non-pregnant women in the vaccine era in Harare, Zimbabwe.
Obi CL; Tswana SA; Moyo SR; Berejena C
Cent Afr J Med; 1996 May; 42(5):135-8. PubMed ID: 8771931
[TBL] [Abstract][Full Text] [Related]
36. [Post-vaccination measles immunity in children on long-term anticonvulsant therapy].
Popović-Miocinović L; Smerdel S; Grubesić Z; Miklousić A
Lijec Vjesn; 1994; 116(3-4):74-8. PubMed ID: 8057741
[TBL] [Abstract][Full Text] [Related]
37. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
Zäch K; Nicoara C; Germann D; Matter L
Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of measles antibodies before and after vaccination in previously unvaccinated children of the Cordillera Province (Santa Cruz Department, Bolivia).
Guglielmetti P; Bianchi Bandinelli ML; Bartoloni A; Gamboa H; Roselli M; Valensin PE
J Trop Med Hyg; 1994 Aug; 97(4):231-5. PubMed ID: 8064946
[TBL] [Abstract][Full Text] [Related]
39. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
[TBL] [Abstract][Full Text] [Related]
40. [Immunologic response and post-vaccination reactions in children vaccinated against measles. II. Antibody levels and seroconversion following vaccination].
Kańtoch M; Naruszewicz-Lesiuk D; Polna I; Lityńska J
Przegl Epidemiol; 1974; 28(3):325-31. PubMed ID: 4471838
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
